Skip to content
Medical Health Aged Care

IVF innovation boosts viable embryo selection: study

Monash University 3 mins read

Researchers at Monash University have developed a light-emitting microchip that can safely measure the energy produced by embryos, a key indicator of embryo health. 

 

Published in the journal Human Reproduction, the research confirmed that advanced imaging technology can be integrated into a microchip for imaging of live mouse embryos. The technology could be used for selecting the healthiest embryos for implantation and subsequent healthy live birth.

 

To demonstrate these benefits in a clinical IVF setting, further work is currently being planned. A collaboration of reproductive science, reproductive medicine and AI specialists at UNSW Sydney, and Mechanical and Aerospace engineers at Monash University will continue supporting the technology with development towards a prototype for clinical testing in humans. If successful, the technology has the potential to make embryo selection faster and safer, while further improving IVF success rates. 

 

The new device is a specially designed optical microchip the size of the kangaroo head on an Australian $1 coin. Using advanced micro lenses, it shines light onto individual embryos, measuring their energy without damaging them. The images are then analysed to determine the health of the embryos.

 

Currently, embryo selection is performed using standard optical microscopes, relying heavily on operator expertise and experience to determine which embryos to select. Many people are also choosing to rely on invasive, expensive and imperfect genetic testing of their embryos to further improve the selection process. Despite the time, cost and risk associated with these procedures, IVF is still only successful 30 per cent of the time and multiple treatment cycles are often needed before a baby is born.

 

Dr Fabrizzio Horta, lead researcher and reproductive scientist has moved to UNSW Sydney from Monash University to progress the research collaboration to clinical trials and AI technology development. Dr Horta said the closest alternative to the new device are complex and expensive research systems that could cost about $1 million and are not suitable for clinical use. 

 

“The novel microchip can be produced for a fraction of that cost, which could enable the development of affordable, multi use devices compatible with the clinical IVF workflow, research and animal industries,” Dr Horta said. 

 

“The device effectively enables us to reconstruct high-resolution images of an embryo’s metabolic activity, or energy, which may signal genetic or metabolic abnormalities. Currently the only alternative for advanced embryo selection in a clinical setting is via embryo biopsy for genetic testing, which is expensive, time consuming and an invasive procedure that could damage the embryos. 

 

“Embryologists typically select embryos by eye, via a superficial examination under a microscope. With this device, we can examine an embryo, charting its cellular energy. This information could assist in selecting the healthiest embryo for treatment.”

 

Monash University has submitted the technology for patent filing based on its novel design and scalability. The research team is now working with Monash University and UNSW to investigate the potential of raising investment and forming a spinout company to commercialise the technology for global adoption. 

 

“This technology will most impact our ability to examine embryo viability at an affordable price. But, we cannot integrate some advanced tech due to its complexities," Dr Horta said.

 

“The most important impact this technology will have is the ability to better examine the embryo viability at an affordable cost, but with significantly advanced technology that we have not been able to integrate clinically due to technology complexities. 

 

This could potentially reduce the time it takes to achieve a healthy baby. It means that, when a couple starts IVF, they could succeed faster instead of, on average, going through multiple rounds of IVF. Those cycles are terrible both emotionally and financially."

 

Read the paper here: DOI: 10.1093/humrep/deae249

 

Dr Fabrizzio Horta is available for interview.

For media enquiries please contact: 

Monash Media
E: media@monash.edu
T: +61 (0) 3 9903 4840

 For more Monash media stories, visit our news and events site

***ENDS***

More from this category

  • Medical Health Aged Care
  • 08/12/2024
  • 07:05
Royal Australian College of GPs

GPs key to addressing Australia’s mental health crisis: RACGP

Patients must have greater funding for mental health care from their GP, as reporting in The Australian that quantifies the severe shortfall of mental health support and the failure of Australia’s mental health system makes clear. This call from the from the Royal Australian College of GPs (RACGP) comes ahead of a soon-to-be-released report that shows an $8 billion shortfall in funding for healthcare including general practice, social services, and housing by immediate past AMA President Professor Steve Robson and ANU head of psychiatry Associate Professor Jeffrey Looi. The RACGP has long called on the Government to address funding and…

  • Contains:
  • Medical Health Aged Care
  • 06/12/2024
  • 22:55
EssilorLuxottica Media Relations

OneSight EssilorLuxottica Foundation Joins Forces with World Health Organization to Advance Global Vision Care Under WHO SPECS 2030 Initiative

OneSight EssilorLuxottica Foundation Joins Forces with World Health Organization to Advance Global Vision Care Under WHO SPECS 2030 Initiative Paris, France and Geneva, Switzerland (6 December 2024) – The OneSight EssilorLuxottica Foundation is proud to announce its collaboration with the World Health Organization (WHO) as a global collaborating partner on the WHO’s SPECS 2030 initiative.The SPECS initiative builds on the world’s first-ever global target to increase effective refractive error coverage by 40% by 2030, which was endorsed by WHO Member States in 2021 at the World Health Assembly. This collaboration between WHO and the Foundation represents a significant step forward in addressing…

  • Medical Health Aged Care, Political
  • 06/12/2024
  • 16:24
Massage & Myotherapy Australia

ANZSCO’s response to Massage & Myotherapy Australia recommended reforms welcomed

Massage & Myotherapy Australia has welcomed reforms to the Australian Bureau of Statistics’ OSCA (formerly ANZSCO) Occupation Standard Classification for Australia list for Massage Therapists 411613. Mrs Ann Davey CEO, said that the long overdue reforms to the old ANZSCO listing, now recognise the three distinct Australian massage occupations. This includes the new Unit Group of 4412 Massage Therapists and Myotherapists, with the three subcategories of 441231 Massage Therapist, 441232 Myotherapist, and 441233 Remedial Massage Therapist. Mrs Davey said, ‘We welcome these changes, because they represent the significant changes in professionalism, training and competency standards that have occurred over the…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.